Health Canada clears Moderna Phase 1 trial for Bundibugyo Ebola vaccine mRNA-1469
MRNA•Health Canada clears Phase 1 trial
Health Canada cleared Moderna’s Phase 1 trial of mRNA-1469, an investigational vaccine targeting Bundibugyo ebolavirus.
CEPI committed up to USD 50 million to support preclinical work, the Phase 1 study, and scaled manufacturing of additional doses.
Related News
Outlook Therapeutics terminates May 13, 2026 prospectus supplement for ATM offering agreement with H.C. Wainwright
OTLK•
PSEG SVP Corporate Citizenship Richard T. Thigpen sells 8,000 common shares worth $596,480
PEG•
